President's Message

Dear RPSC members,

I am excited about the upcoming year and would like to thank you all for your continued support and active participation in RPSC activities during pandemic COVID-19. Radiochemistry and radiopharmacy continue to be an important part of SNMMI and we are proud to represent this community.

The RPSC (co)-sponsored webinars offered at the 2020 Annual Meeting (virtual) and 2021 Mid-Winter Meeting (virtual) including Best practices to Support the Quality Control of PET Drugs, Basic Science Summary Session, RPSC Young Investigator Symposium, and From First-in-Human to Reimbursement: A Practical Guide to PET Tracer Development were all high quality and well-received. If you have any recommendation for upcoming RPSC session or other strategical ideas, we would love to hear from you.

Furthermore, we are proud to continue to support the prestigious Michael J. Welch Award which was awarded this year to Henry VanBrocklin, PhD, FSNMMI, of the University of California, San Francisco (UCSF). His talk "Life is Like a Box of Chocolates: A Molecular Imaging Journey" was truly outstanding and was enjoyed by both junior and senior investigators.

Our RPSC young investigator awards symposium offers the chance for our rising stars to showcase their recent scientific achievements and is always one of the highlights of the Annual Meeting for many of us. I would particularly like to congratulate Drs. Rocío, Outi and Ian for winning 1st, 2nd, and 3rd place in the symposium respectively.

As we finalize our planning for 2021, I look forward to our ongoing education and scientific activities as well as social virtual events such as our RPSC/CMIIT Drink & Think which provides opportunities for networking and online scientific discussions.

Hope 'see' you all in the coming SNMMI Virtual Annual Meeting, June 11-15, 2021!

Steven Liang, PhD, RPSC President
Recent RPSC-Sponsored Sessions

The Radiopharmaceutical Sciences Council (RPSC) was pleased to sponsor one continuing education (CE) session and one Young Investigator Award (YIA) Symposium at the June 2020 SNMMI Virtual Annual Meeting and co-sponsored Basic Science Summary Session with CMIIIT. In addition, RPSC continued to support the Michael J. Welch, PhD Award and Lecture (webinar on November 4, 2020) and sponsored a CE session “From First-in-Human to Reimbursement: A Practical Guide to PET Tracer Development” as part of Mid-Winter Virtual Meeting (webinar on February 25, 2021). All of the sessions were well-attended, and the following is a brief summary:

“Best Practices to Support the Quality Control of PET Drugs” - Three experts on the QC of PET drugs, Sally Schwarz from Washington University School of Medicine, Denise Jeffers from the University of Alabama at Birmingham, and Amy Vavere, PhD. from St. Jude Children’s Research Hospital gave outstanding lectures that brought together the basic sciences and the regulatory requirements involved in the quality control of PET drugs. Drs. Amy Vavere from St. Jude Children's Research Hospital and Svetlana Selivanova from CHU de Québec Research Centre and Université Laval organized and moderated the session.

“RPSC Young Investigator Award Symposium” - This session highlighted young scientists and junior faculty members who contribute the recent advances in molecular targeting probes of various human diseases and translational radiochemical methods. The seven speakers were selected from the top-rated SNMMI AM abstracts from nearly 150 submissions and the session covered a wide range of topics, including radiochemical methodology development, novel targeted probes, theranostic pairs etc. Presentations were given by seven rising stars to showcase their recent work, followed by intensive questions from audiences and RPSC judges. Three out of seven speakers were finally selected based on their scientific content, overall presentation, and responses to questions. Three awardees and their work are also highlighted in the RPSC 2020-2021 Award Winners of this newsletter. Thank you to all presenters (their name, presentation title and affiliation at the time are listed below). Drs. Peter Scott from the University of Michigan and Steven Liang from Massachusetts General Hospital and Harvard Medical School organized and moderated the session.

<table>
<thead>
<tr>
<th>Presentation title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pretargeted Theranostic Radioimmunotherapy with a Cu-64/Cu-67 Isotopologue Pair</td>
<td>Outi Keinaenen</td>
</tr>
<tr>
<td>Delta-like Ligand 3 (DLL3) is a novel target for molecular imaging of Neuroendocrine Prostate Cancer</td>
<td>Joshua Korsen</td>
</tr>
<tr>
<td>Direct Aromatic [F]Fluorination of Tetrazines: A Rapid and Convenient Entry to Tetrazines for Pretargeted PET Imaging</td>
<td>Rocio García Vázquez</td>
</tr>
<tr>
<td>Simple synthesis and use of [C]Carbonyl difluoride for the intracyclic labeling of heterocycles</td>
<td>Erik Jimmy Jakobsson</td>
</tr>
<tr>
<td>Translation of [F]SIFAlin-TATE to the clinic: Radiosynthesis, biodistribution and first clinical results</td>
<td>Simon Lindner</td>
</tr>
<tr>
<td>Enhancing Tumor Uptake for [Lu]-Labeled MC1R Targeting Radioligands by Combining N-Methylations with an Zalumin Binder</td>
<td>Chengcheng Zhang</td>
</tr>
</tbody>
</table>

“Michael J. Welch, PhD Award and Lecture” - This year’s award recipient is Henry VanBrocklin, PhD, of the University of California, San Francisco (UCSF). Henry is a Professor of Radiology, Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI) at the UCSF, and he is a Joint Faculty Scientist at the Lawrence Berkeley National Laboratory. His research interests include short-lived radioisotope production to the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparations and applications. Dr. VanBrocklin presented “Life is Like a Box of Chocolates: A Molecular Imaging Journey” during the Michael J. Welch, PhD, Award Session held on November 4, 2020. Thank you to Peter Scott, PhD, who organized and moderated the session. And a very special Congratulations to Dr. Henry VanBrocklin for winning this award!

Recorded Webinar link
“From First-in-Human to Reimbursement: A Practical Guide to PET Tracer Development” – Sponsored by the RPSC this CE session covered the steps involved in the translation of PET tracers to humans. In the first talk, Dr. Michael Nickels, Associate Professor of Radiology and director of the Cyclotron Facility and Nuclear Pharmacy at the Washington University in St. Louis covered the basics of the production of PET tracers for human use including the quality control tests. Next, Dr. Corinne Beinat, Instructor of Radiology at Stanford, discussed other aspects that go into an IND or eIND application including dosimetry and toxicology studies to obtain clearance from the FDA to initiate human studies. Finally, Dr. David Schuster, Professor of Radiology and Imaging Sciences and Director of the Division of Nuclear Medicine and Molecular Imaging at Emory University in Atlanta, described the design and milestones of phase II and phase III studies and what is needed for NDA approval and future insurance reimbursement. One of the aspects that all the speakers agreed on was on the importance of communicating early and often with the FDA to ensure that the specific details of the studies being proposed will meet the requirements. This session was organized and moderated by RPSC Board Members Drs. Pedro Brugarolas and Steven Liang from Massachusetts General Hospital and Harvard Medical School. Thank you for organizing and moderating the session.

2020-2021 RPSC/CMIIT Drink & Think Session

The RPSC and the Center for Molecular Imaging Innovation and Translation (CMIIT) co-sponsored the highly popular Drink &Think Event as virtual webinars and informal online discussion during 2020-2021.

The Drink &Think provides attendees the opportunity to discuss emerging research topics, share laboratory management and grant writing experience, enjoy refreshments (i.e., drinks) at home, and ‘think’ with professional colleagues.

A big ‘thank you’ goes out to our wonderful ‘Drink & Think’ organizing committee members (alphabetical order): Cathy Cutler (Brookhaven National Laboratory), Michelle L. James (Stanford University), Steven Liang (Massachusetts General Hospital and Harvard Medical School), Dustin Osborne (the University of Tennessee), Reiko Oyama (Washington University at St. Louis), Alan Packard (Boston Children’s Hospital and Harvard Medical School), Peter Scott (the University of Michigan) and Daniel Yokell (Massachusetts General Hospital and Harvard Medical School)

The following is a summary:

Radiochemist / Radiopharmacist Drink & Think (September 28, 2020): Discuss current issues you are facing in your labs during COVID 19 - Help us help you!

Radiochemist / Radiopharmacist Drink & Think (November 2, 2020): Are you ready for the USP <825>?

Radiochemist / Radiopharmacist Drink & Think (December 7, 2020): Young Investigators Town Hall


Recorded Webinar link
Congratulations RPSC 2020-2021 Award Winners!

Michael J. Welch, PhD, Award

The Michael J. Welch, PhD Award was created as a means of recognizing individuals who have made an outstanding contribution to the field of radiopharmaceutical sciences, have been involved in mentoring students, postdoctoral fellows and junior faculty, and have been involved in community service to the field of radiopharmaceutical chemistry and molecular imaging. This award is funded through an endowed gift given to the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) by the Dr. Michael J. Welch Foundation in memoriam of Professor Michael J. Welch, PhD.

The 2020 MJW award recipient is Henry VanBrocklin, PhD, PhD, of the University of California, San Francisco (UCSF). Henry is a Professor of Radiology, Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI) at the UCSF, and he is a Joint Faculty Scientist at the Lawrence Berkeley National Laboratory. His research interests include short-lived radioisotope production to the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparations and applications. Dr. VanBrocklin presented “Life is Like a Box of Chocolates: A Molecular Imaging Journey” during the Michael J. Welch, PhD, Award Session held on November 4, 2020.

Congratulations Henry!

Recorded Webinar link

Michael J. Welch, PhD, Postdoctoral Travel Grant Award

The purpose of the Michael J. Welch post-doctoral travel award is to recognize an outstanding abstract by a young investigator in the area of radiochemistry. The award will be given to the highest ranked abstract submitted by a young investigator in the molecular targeting probes, novel radiochemistry and chelation track. This award is funded through an endowed gift given to the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) by the Dr. Michael J. Welch Foundation in memoriam of Professor Michael J. Welch, PhD.

This year's award recipient is Zhen Yang, PhD, of the Houston Methodist for his winning abstract entitled, “Small molecule-based angiogenic radionuclide radiation therapy combined with anti-PD1 immune checkpoint blockade for triple-negative breast cancer”

Congratulations Zhen!

Berson-Yalow Award

The Berson-Yalow Award celebrates the contributions of Solomon A. Berson, MD, and Rosalyn S. Yalow, PhD (Nobel Laureate 1977), who pioneered the principle of the competitive binding assay and used it to develop the field of radioimmunoassay, which become a mainstay of early nuclear medicine. Since radioimmunoassay is no longer used extensively, this award will continue to recognize outstanding original work in the field of Nuclear Medicine and recognize the use of competitive receptor-binding assays in vitro and/or in vivo.

Congratulations to the 2020 Berson-Yalow Award Winner - Reinier Hernandez, PhD. Dr. Hernandez won for the abstract entitled: “GD2/B7-H3 bispecific antibodies for next-generation neuroblastoma treatment”. Dr. Hernandez is now an assistant professor in the Department of Medical Physics at the University of Wisconsin, Madison.
Hal O’Brien Rising Star Award

The Rising Star Award was created to celebrate the leadership legacy of the High Country meeting for its 40th anniversary. Those of us who attend the HCNMC truly appreciate Dr. Hal O’Brien’s vision in creating such a unique format that brings together leaders from all branches of nuclear medicine and molecular imaging. To recognize this legacy, and to provide the next generation of leaders the opportunity to benefit from this unique learning experience, the Hal O’Brien fund was established at the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF).

Nominated by our RPSC and selected by the Hal O’Brien Rising Star Award Committee and the High Country Nuclear Medicine Organizing Committee, Benjamin Larimer, PhD, University of Alabama Birmingham, is the award recipient of 2020, along with three other awardees, including Thomas Hope, MD, University of California, SF, nominated by the SNMMI Correlative Imaging Council; Venkatesh Murthy, M.D., Ph.D., University of Michigan, nominated by ASNC and James Thackeray, Ph.D. Hannover Medical School, nominated by the SNMMI Cardiovascular Council. Congratulations Ben!

RPSC Young Investigator Awards (YIAs)

The RPSC YIAs are reserved for the best scientific abstracts on radiopharmaceutical chemistry in nuclear medicine by young investigators. These awards were presented virtually during the 2020 SNMMI Annual Meeting. Congratulations to the following YIA winners pictured below:

Rocio García Vázquez – 1st Place
Outi Keinaenen – 2nd Place
Ian R. Duffy – 3rd Place

Rocio García Vázquez is originally from Spain, she studied her Bachelor’s Degree in Chemistry, followed by a Master’s Degree in Pharmacological Research at the Autonomous University of Madrid (Spain). Currently, she is a PhD student in the Matthias Herth group at the University of Copenhagen. At the PET-AphaSy Network Consortium, her main work so far has focused on the development of tetrazines for pre-targeted imaging using direct fluorine-18 labeling approaches. Her presentation at the RPSC YIA entitles: “Direct Aromatic 18F-labeling of Tetrazines: A Rapid and Convenient Entry to Tetrazines for Pretargeted PET Imaging”.

Outi Keinaenen gained her PhD diploma in radiopharmaceutical chemistry in 2018 from the University of Helsinki, Finland (Thesis Advisors: Drs. Anu J. Airaksinen and Mirkka Sarparanta). She started her postdoctoral training under the supervision of Dr. Brian M. Zeglis in 2018 at Hunter College of the City University of New York, New York, NY, USA. Recently, she received Academy of Finland Postdoctoral Fellowship (2020-2023) to continue her research under the supervision of Dr. Zeglis. Her presentation at the RPSC YIA entitles: “Pretargeted Theranostic Radioimmunotherapy with a Cu-64/Cu-67 Isotopologue Pair”.

Ian Duffy completed his undergraduate degree in Chemistry (honours designation) at the University of British Columbia (UBC), followed by a doctorate in physical organic chemistry at McMaster University. He next completed a postdoctoral fellowship at the Centre for Addiction and Mental Health (CAMH) under the supervision of Dr. Vasdev. He currently holds the role of Scientist II: Radiochemistry at Fusion Pharmaceuticals. His presentation at the RPSC YIA entitles: “Copper(I)-mediated $^{11}$C-carboxylation of (hetero)arylstannanes: radiosynthesis of $[^{11}$C]bexarotene”. 

RPSC Newsletter – Spring 2021
Thank you RPSC Officers and Board Members for your service in 2018-2020!

- **David Dick, PhD**, University of Iowa – Immediate Past President (2019-2020), President (2018-2019), Vice President (2017-2018), Vice President-Elect (2016-2017), Secretary and Board member (2012-2016)
- **Naga Vara Kishore Pillarsetty, PhD**, Memorial Sloan Kettering Cancer Center - Secretary (2018-2020)
- **Ephraim Parent, MD, PhD**, Mayo Clinic – Board Member (2018-2020)
- **Xiankai Sun, PhD**, UT Southwestern Medical Center – Board Member (2018-2020)

Current RPSC Officers, Board Members, and Interns

**President**

**Dr. Steven H. Liang** is the Director of Radiochemistry and Biomarker Development, Nuclear Medicine and Molecular Imaging at Massachusetts General Hospital (MGH) and Associate Professor of Radiology, Harvard Medical School. Dr. Liang received his PhD in Synthetic Chemistry (advisor: Prof. Ciufolini) from UBC and then performed postdoctoral research at Harvard (advisor: Prof. E.J. Corey). In 2012, Dr. Liang was recruited to MGH and Harvard Medical School, where he started his independent research in radiochemistry and radiopharmaceutical development. Dr. Liang's basic science training in the field of chemistry helps him to develop novel radiochemistry to prepare new PET probes and radiopharmaceuticals for clinical applications. His work also focuses on the discovery of small molecule-based PET biomarkers for important yet underexplored neurological receptors, transporters and enzymes, and the subsequent transition of these new diagnostics into the clinic. Dr. Liang has contributed more than 120 peer-reviewed publications and his work has been recognized by several national and international awards, as well as continuously supported by multiple federal and foundation grants.

**Vice President**

**Dr. Amy Vavere** earned a PhD in Chemistry (MJ Welch, PhD) and postdoctoral fellowship (JS Lewis, PhD) at Washington University in St. Louis, then brought her experience to St. Jude Children’s Research Hospital as Head Radiochemist in 2007. She became Director of a rebranded Molecular Imaging Core in 2018 as it transitioned to a shared resource within Diagnostic Imaging. She has been a research leader in the department initiating preclinical and clinical imaging collaborations with dozens of investigators while expanding the portfolio of available PET tracers. Amy has been a member of RPSC’s Board of Directors since 2015 as Director, Treasurer, and now VP. She heads the Programmatic Working Group in the DE&I Task Force and is Vice-Chair of Molecular Probes for the Scientific Programming Committee.

**Vice President-Elect**

**Dr. Michael Nickels** is the director of the Mallinckrodt Institute of Radiology’s (MIR) Cyclotron Facility and Nuclear Pharmacy at Washington University in St. Louis. As director he oversees all aspects of day-to-day operation and future initiatives for which the facility is uniquely qualified to spearhead. Prior to joining the faculty at MIR, Nickels served as the director of the Radiochemistry Core Laboratories at Vanderbilt University Medical Center (VUMC). Dr. Nickels received his PhD in Chemistry from the University of Illinois at Urbana-Champaign and moved to VUMC for a post-doctoral appointment. In his tenure with Vanderbilt, Nickels oversaw the expansion of the radiochemistry core and its ability to produce a variety of radioactive imaging agents for both preclinical and clinical research utilization. The agents developed included common isotopes and up-and-coming “boutique” isotopes. Since
arriving at MIR, Nickels has focused on growing the international footprint of an already world-class production facility, including new and innovative industrial collaborations, clinical research projects, basic radiochemical science and radionuclide production/distribution.

Past immediate President

Dr. Peter Scott started his independent career at the University of Michigan in 2009. He is currently an Associate Professor Radiology and Pharmacology, Director of the UM PET Center, and Faculty Scientist in Medicinal Chemistry and the Rogel Cancer Center. Scott’s group is involved in all aspects of the Radiopharmaceutical Sciences including i) developing new methods for radiolabeling bioactive molecules, ii) cGMP radiopharmaceutical manufacture, iii) development of radiotracers for PET imaging of CNS disorders, and iv) application of new technology (e.g., automation, machine learning) to radiochemistry. He has published over 125 papers and edited 5 books, including a brand-new edition of the Handbook of Radiopharmaceuticals published by Wiley in 2021.

Secretary

Dr. Ephraim Parent is an Assistant Professor of Radiology at Mayo Clinic and is a dual boarded radiologist and nuclear medicine physician. He received his PhD in Chemistry from the University of Illinois at Urbana-Champaign under the direction of Dr. John Katzenellenbogen and obtained his MD at the University of Illinois at Chicago. He completed radiology residency and nuclear medicine fellowships at Washington University in St. Louis. Current clinical research projects include, among others, ¹⁸F-fluciclovine PET evaluation of intracranial malignancies. He currently serves on both national and regional organizations including co-chair of the SNMMI prostate cancer outreach working group.

Treasurer

Dr. Svetlana Selivanova is radiopharmaceutical chemist and currently oversees the design and construction of a new PET cyclotron and radiopharmaceutical facility at CHU de Quebéc–Université Laval hospital. She is also a researcher at CHU de Quebéc Research Centre and an adjunct professor at the Faculty of Pharmacy, Université Laval. She earned her MSc in chemistry from Peoples’ Friendship University of Russia and PhD in radiopharmaceutical chemistry and radiobiology from Université de Sherbrooke (Canada). Before joining CHU de Quebéc–Université Laval, she held several research positions including at the Sherbrooke University Hospital and at the Center for Radiopharmaceutical sciences ETH Zurich. Dr. Selivanova’s research interests are multidisciplinary and encompass development and application of small-molecule radiolabeled compounds for molecular imaging and in support of drug development.

RPSC Board of Directors

Dr. Pedro Brugarolas obtained a PhD in Chemistry from the University of Chicago in 2012 and completed postdoctoral training in PET tracer development and Radiochemistry at the University of Chicago and the National Institute of Mental Health of the National Institutes of Health (NIH/NIMH). Since 2018, he works as an Assistant Professor in Gordon Center for Medical Imaging at the Massachusetts General Hospital (MGH) and Harvard Medical School. At MGH, his lab focuses on developing novel tracers for brain imaging and new radiolabeling methods. Recently, Dr. Brugarolas and his colleagues at MGH started the first human study with [¹⁸F]3F4AP a novel tracer that targets K⁺ channels in the brain for demyelinating disease.
**Dr. Michelle James** is an Assistant Professor in the Department of Radiology and Neurology, within the Molecular Imaging Program at Stanford (MIPS). She received her BS in pharmacology and organic chemistry at the University of Sydney, where she also earned her PhD in radiochemistry/pharmacology and was awarded the University Medal. For over fifteen years, Dr. James’s research has focused on designing, evaluating, and translating novel molecular imaging agents to improve the way we diagnose, treat, and understand devastating neurological disease. In particular, she is interested in developing new positron emission tomography (PET) radiotracers for visualizing neuroinflammation with the goal of learning about the in vivo role, spatiotemporal dynamics, and different functional phenotypes of specific innate and adaptive immune cells throughout the progression of Alzheimer’s disease, multiple sclerosis, and stroke. Dr. James is also very interested in applying these tools to guide therapeutic selection for individual patients and as imaging biomarkers in clinical trials. As part of her work, Dr. James has multiple patented radiotracers, four of which are currently being used in clinical neuroimaging studies at Stanford and/or around the world. She also cofounded a company called Willow Neuroscience with is focused on developing immunomodulatory therapeutics and novel PET diagnostics for neurodegenerative diseases.

**Dr. Kai Chen** is an Associate Professor of Radiology at the University of Southern California. The research interests in Dr. Chen’s laboratory focus on the development of novel molecular probes for disease diagnosis and treatment. Dr. Chen has published over 70 peer-reviewed articles, and he is a co-inventor of 22 International and US patents. He has served as a reviewer for several funding agencies and an active reviewer for over 70 research journals. Dr. Chen is using his experiences in academia and industry settings to enthusiastically find common ground among all types of scientists in the organization, continue to promote the goals of the RPSC, facilitate the translation process of radiopharmaceutical-enabled imaging and therapy into patient care, and offer exceptional professional education.

**Dr. Jonathan Engle** is an assistant professor in the Medical Physics Department of the University of Wisconsin with 15 years’ experience in radionuclide production, accelerator targetry and radiochemistry, and PET imaging. He received his PhD from the University of Wisconsin and trained as a postdoc at Los Alamos National Laboratory as a Frederick Reines Fellow. His research contributed to a national supply of the alpha-therapy isotope 225Ac, nuclear databases and theoretical models in the 100-800 MeV (incident H+) range, and to large-scale production of many radionuclides. In 2016, Dr. Engle joined the University of Wisconsin Departments of Medical Physics and Radiology, where he leads the Cyclotron Research Group. His research is focused on production of positron- and low energy, electron-emitting radionuclides.

**Board Liaison – SNMMI President**

**Dr. Alan Packard** received his BS in Chemistry from the University of New Hampshire and his PhD in Inorganic Chemistry from Colorado State University, where he studied Jahn-Teller distortions in copper complexes. His first exposure to nuclear medicine was synthesizing 99Tc-aminopolyacrylate complexes as a postdoc at the University of Cincinnati after which he spent two years at Brookhaven National Laboratory where he continued his investigations into technetium chemistry. In 1982, he moved to Boston Children’s Hospital where he is now a Sr. Research Associate and Director of Radiopharmaceutical Research and an Associate Professor at Harvard Medical School. His research interests still include radiometals, primarily 64/67Cu and 89Zr, but now also include 18F where his group has developed a promising 18F-labeled myocardial perfusion agent.
Council Interns

**Dr. Jessica Comstock** received a PharmD in 2016 from Purdue University College of pharmacy and became a Board-Certified Nuclear Pharmacist in 2018. Currently she is the Director of Quality and Regulatory for PharmaLogic Holdings. She oversees 36 nuclear pharmacies and 8 PET manufacturing facilities. Jessica is also involved in the American Pharmacist Association as the Chair of the New Practitioner Advisory Committee.

**Dr. Allie Sowa Dumond** was born and raised in Michigan and defended her Ph.D. in 2018 in Dr. Peter Scott’s lab at the University of Michigan on research towards the development of novel GAT-1 targeted PAT radiotracers. As a Research Laboratory Specialist at the Michigan Medicine PET and Radiochemistry Facility, she is responsible for clinical production of PET radiotracers, training of new staff, in addition to research developing novel PET radiotracers and integration of new-to-site synthesis and equipment into the current lab workflow.

SNMMI Staff Liaison

**Teresa Ellmer, MIS, CNMT** is the Associate Director, Governance, SNMMI and RSPC staff liaison. Prior to joining the SNMMI in 2015, Teresa was a nuclear medicine technologist with over 25 years’ experience in the clinic.
Call for Nominations - 2021 Radiopharmaceutical Sciences Council

Dear Members of the Radiopharmaceutical Sciences Council (RPSC):

The nominating committee is seeking nominations for the 2020 RPSC Board of Directors election, through April 3.

Candidates are sought for the following positions:

- **Vice President-Elect** (one-year term, will assume Vice President role in 2022 and assume presidency in 2023)
- **Treasurer** (two-year term)
- **TWO At-Large Board Members** (two-year term)

Elected individuals will begin their term at the conclusion of the SNMMI Annual Meeting in June 2021 and should plan on attending all RPSC Board meetings (2-3 per year) and conference calls.

This is a great opportunity to get involved in RPSC activities and we hope that, with your help, we are able to create a slate of candidates that will work hard to achieve the goals of this Council.

**NOMINATION PROCESS:**

Nominations should be submitted to tellmer@snmmi.org by April 3.

- Nominations must include CV, 2-3 paragraph biosketch and platform statement and a photo.
- Nominees must be a member of the council
- Self-nominations welcome and encouraged!

If you have questions about the nomination process or the responsibilities of a council board member, please contact Teresa Ellmer, Associate Director of Governance (tellmer@snmmi.org, 703-652-6780).

Please help us by nominating creative leaders who shall continue to build the success of this council and support the mission of the Society. Thank you!

Please nominate your colleagues and/or yourself for these RPSC positions!
2021 RPSC virtual business retreat

first row (from left to right): Jon Engle, Kai Chen, Michelle James, Allie Dumond
second row: Steven Liang, Pedro Brugarolas, Peter Scott, Jessica Comstock
third row: Ephraim Parent, Mike Nickels, Amy Vavere, Svetlana Selivanova
Photo courtesy by Teresa Ellmer

See you in SNMMI 2021 Virtual Annual Meeting – June 11-15, 2021!